/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. AI For Pharma Growth
  2. E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named
E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named

E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named

AI For Pharma Growth · Sep 1, 2026

Pharma's AI training fails. Generic programs don't create lasting capability. The solution is maintained, role-specific training for workflows.

Incomplete Pharma AI Training Creates 'Funded Risk' by Boosting Usage Without Judgment

Training that raises employee enthusiasm for AI tools without embedding deep, contextual judgment is counterproductive. It increases AI use in high-stakes workflows faster than the organization's ability to control for errors, creating a risk funded by the training budget itself and leaving the company more exposed than before.

E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named thumbnail

E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named

AI For Pharma Growth·3 months ago

Approved Enterprise Software Becomes a 'Trojan Horse' for Unvetted AI Features

A significant, overlooked risk is that existing, fully approved software is constantly updated with new AI features. These capabilities are added post-procurement and bypass initial compliance and regulatory checks, introducing unvetted AI into sensitive, regulated workflows without anyone noticing, creating a major governance blind spot.

E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named thumbnail

E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named

AI For Pharma Growth·3 months ago

Pharma AI Training Fails Because Judgment Skills Erode 3x Faster Than Procedural Ones

AI skills decay over time, but cognitive, accuracy-dependent skills (like judging a regulator-facing output) erode three times faster than procedural skills (running a workflow). Companies often measure the slower-decaying half, missing the critical loss of judgment capability, which carries the most regulatory consequence.

E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named thumbnail

E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named

AI For Pharma Growth·3 months ago

Generic AI Training Fails Pharma by Teaching the Tool, Not Workflow-Specific Judgment

Company-wide learning platforms are insufficient for pharma because they teach general AI principles. They fail to address the specific, high-stakes judgments required in functional workflows, like deciding if a generated regulatory summary is defensible or a promotional claim is substantiated, leaving employees with unanswered questions for their roles.

E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named thumbnail

E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named

AI For Pharma Growth·3 months ago

The EU AI Act's 'Context of Use' Clause Makes Generic AI Training a Compliance Risk

The EU AI Act's Article 4 creates a literacy duty requiring training to account for the 'context in which it is used.' This elevates the standard from generic awareness to role-specific capability. A completion record from a generic program is insufficient documentation for this regulatory requirement, which applies even to non-EU firms whose AI output is used in the EU.

E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named thumbnail

E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named

AI For Pharma Growth·3 months ago

Employee 'Shadow AI' Use Signals a Failure in Corporate Tooling, Not Just a Compliance Breach

When employees use unapproved AI tools, it shouldn't be seen merely as a compliance violation. It is often a strong signal that the officially sanctioned tools and training are inadequate for their workflow needs. This behavior highlights a critical gap in the company's enablement strategy that needs to be addressed proactively.

E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named thumbnail

E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named

AI For Pharma Growth·3 months ago

Peak AI Confidence in Employees Can Signal Dangerous 'Over-Reliance,' Not Mastery

An employee's AI journey often includes an 'over-reliance' stage, where enthusiasm leads them to unknowingly outsource their thinking. This stage feels like peak performance and confidence to the user, making it invisible on standard satisfaction surveys and creating a significant hidden risk for the organization.

E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named thumbnail

E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named

AI For Pharma Growth·3 months ago